The projected effect of risk factor reduction on Alzheimer's disease prevalence
- PMID: 21775213
- PMCID: PMC3647614
- DOI: 10.1016/S1474-4422(11)70072-2
The projected effect of risk factor reduction on Alzheimer's disease prevalence
Abstract
At present, about 33·9 million people worldwide have Alzheimer's disease (AD), and prevalence is expected to triple over the next 40 years. The aim of this Review was to summarise the evidence regarding seven potentially modifiable risk factors for AD: diabetes, midlife hypertension, midlife obesity, smoking, depression, cognitive inactivity or low educational attainment, and physical inactivity. Additionally, we projected the effect of risk factor reduction on AD prevalence by calculating population attributable risks (the percent of cases attributable to a given factor) and the number of AD cases that might be prevented by risk factor reductions of 10% and 25% worldwide and in the USA. Together, up to half of AD cases worldwide (17·2 million) and in the USA (2·9 million) are potentially attributable to these factors. A 10-25% reduction in all seven risk factors could potentially prevent as many as 1·1-3·0 million AD cases worldwide and 184,000-492,000 cases in the USA.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures


Comment in
-
Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal.Lancet Neurol. 2011 Sep;10(9):778-9. doi: 10.1016/S1474-4422(11)70145-4. Epub 2011 Jul 19. Lancet Neurol. 2011. PMID: 21775212 No abstract available.
Similar articles
-
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data.Lancet Neurol. 2014 Aug;13(8):788-94. doi: 10.1016/S1474-4422(14)70136-X. Lancet Neurol. 2014. PMID: 25030513
-
[Prevention of Alzheimer's dementia in Germany : A projection of the possible potential of reducing selected risk factors].Nervenarzt. 2016 Nov;87(11):1194-1200. doi: 10.1007/s00115-015-0045-1. Nervenarzt. 2016. PMID: 26781245 German.
-
Importance of Accounting for Regional Differences in Modifiable Risk Factors for Alzheimer's Disease and Related Dementias: The Case for Tailored Interventions.J Alzheimers Dis. 2022;89(2):563-570. doi: 10.3233/JAD-220278. J Alzheimers Dis. 2022. PMID: 35938249 Free PMC article.
-
Epidemiology and prevention of stroke: a worldwide perspective.Expert Rev Neurother. 2012 Feb;12(2):199-208. doi: 10.1586/ern.11.99. Expert Rev Neurother. 2012. PMID: 22288675 Free PMC article. Review.
-
The epidemiology of the dementias: an update.Curr Opin Psychiatry. 2007 Jul;20(4):380-5. doi: 10.1097/YCO.0b013e32816ebc7b. Curr Opin Psychiatry. 2007. PMID: 17551353 Review.
Cited by
-
Alzheimer's Disease: Treatment Strategies and Their Limitations.Int J Mol Sci. 2022 Nov 12;23(22):13954. doi: 10.3390/ijms232213954. Int J Mol Sci. 2022. PMID: 36430432 Free PMC article. Review.
-
Subjective cognitive impairment subjects in our clinical practice.Dement Geriatr Cogn Dis Extra. 2014 Nov 11;4(3):419-30. doi: 10.1159/000366270. eCollection 2014 Sep. Dement Geriatr Cogn Dis Extra. 2014. PMID: 25538726 Free PMC article.
-
White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?JAMA Neurol. 2013 Apr;70(4):455-61. doi: 10.1001/jamaneurol.2013.1321. JAMA Neurol. 2013. PMID: 23420027 Free PMC article.
-
Prevalence of Alzheimer's disease in rural and urban areas in Cuba and factors influencing on its occurrence: epidemiological cross-sectional protocol.BMJ Open. 2022 Nov 2;12(11):e052704. doi: 10.1136/bmjopen-2021-052704. BMJ Open. 2022. PMID: 36323463 Free PMC article.
-
Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease.Nat Commun. 2013;4:1495. doi: 10.1038/ncomms2494. Nat Commun. 2013. PMID: 23422663
References
-
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186–91. - PubMed
-
- [Accessed January 10, 2011];2010 Alzheimer's Disease Facts & Figures. 2010 at http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf.
-
- O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2010 [Epub ahead of print] - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical